Evidence map›Paper›PMID 27898586›Full record

ReviewCurrent opinion in endocrinology, diabetes, and obesity2017

An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.

Daniel S Hsia, Owen Grove, William T Cefalu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in endocrinology, diabetes, and obesity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 252 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 12 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 12 syntheses or guidelines pooled it, 491 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Daniel S HsiaPennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Owen Grove
William T Cefalu
Pennington Biomedical Research Center · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Pregnane and Glycosides and Obesity/llya RaskinP50AT002776 · NCCIH · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI RIBNICKY, DAVID M · 2005 to 2019
$24.9M
NCCIH NIH HHS P50 AT002776NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

purpose of reviewSodium-glucose co-transporter-2 (SGLT2) inhibitors are the newest class of oral antihyperglycemic agents that have been approved for the treatment of diabetes mellitus. Over the past year, there have been significant developments in both the safety and efficacy of this class of medications that are presented in this review. RECENT

findingsApart from data on the glucose-lowering effect of SGLT2 inhibitors, other metabolic benefits have been demonstrated for this class of medications. Moreover, there have been three Food and Drug Administration Drug Safety Communications issued in 2015 that have led to additional drug labeling. The basic mechanism of action, indications, glucose-lowering benefits, other metabolic benefits, and adverse side-effects of SGLT2 inhibitors are presented in this review. SUMMARY: SGLT2 inhibitors are medications that have a unique mechanism of action and that lower glucose independent of insulin. Given the recent findings on efficacy and benefits, these agents are rapidly establishing their role in the treatment of diabetes. Especially in patients with type 2 diabetes not willing or not ready to start insulin, SGLT2 inhibitors may be another option in those patients requiring additional glucose lowering and in those with acceptable risk factor profiles. Although there appears to be some positive benefits in cardiovascular endpoints, more research on the long-term outcomes in people taking SGLT2 inhibitors is warranted.

Indexed as

Sodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsCanagliflozinDiabetes MellitusDiabetes Mellitus, Type 2GlucoseGlucosidesHumansHypoglycemic AgentsInsulinSodiumBenzhydryl CompoundsCanagliflozindapagliflozinempagliflozinGlucoseGlucosidesHypoglycemic AgentsInsulinSodiumSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID27898586
PMCPMC6028052
OpenAlexW2551481457

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.